Back to News
Market Impact: 0.15
Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Source: Nasdaq
Healthcare & BiotechCorporate EarningsCompany Fundamentals
Mineralys Therapeutics reported $624.7 million in cash, cash equivalents and investments as of September 30, 2026, versus $656.6 million previously; the comparison date is cut off in the article text. The excerpt provides no further financial results or corporate-update details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request
- Tapestry CEO on Earnings Beat, Consumer Outlook